Mostrar o rexistro simple do ítem
Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago
dc.contributor.author | Elberdín, Laida | |
dc.contributor.author | Fernández Torres, Rosa María | |
dc.contributor.author | Paradela de la Morena, Sabela | |
dc.contributor.author | Mateos, María | |
dc.contributor.author | Blanco, Eva | |
dc.contributor.author | Balboa-Barreiro, Vanesa | |
dc.contributor.author | Gómez-Besteiro, María I. | |
dc.contributor.author | Outeda, María | |
dc.contributor.author | Martín-Herranz, Isabel | |
dc.contributor.author | Fonseca, Eduardo | |
dc.date.accessioned | 2022-05-20T07:35:36Z | |
dc.date.available | 2022-05-20T07:35:36Z | |
dc.date.issued | 2022-02-28 | |
dc.identifier.citation | Elberdín, L., Fernández-Torres, R.M., Paradela, S. et al. Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago. Dermatol Ther (Heidelb) 12, 761–770 (2022). https://doi.org/10.1007/s13555-022-00693-2 | es_ES |
dc.identifier.issn | 2190-9172 | |
dc.identifier.uri | http://hdl.handle.net/2183/30708 | |
dc.description.abstract | [Abstract] Introduction: The aim of this study was to evaluate response and drug survival of biologic therapy in patients with moderate to severe plaque-type psoriasis who initiated biologic therapy at least 10 years ago, in a real-world setting. Methods: This was an observational retrospective follow-up study that included patients with moderate to severe plaque-type psoriasis who initiated biologic therapy between October 2006 and December 2009. Efficacy was expressed as the percentage of patients achieving a 50, 75 and 90% reduction from baseline in the Psoriasis Area and Severity Index (PASI 50, PASI 75, PASI 90, respectively) every 3 months during the first year of therapy and then every 12 months up to the end of follow-up or withdrawal from the study. Results: A total of 56 patients were included in the study, representing 140 treatment lines (median 2, range 1-8); of these patients, 53 were still receiving biologic therapy at the end of the study. The mean duration of biologic therapy was 140.4 (range 47.6-175.4) months. Etanercept was used in 98.2% of patients, followed by efalizumab (42.9%), adalimumab (41.1%), ustekinumab (33.9%) and infliximab (16.1%). Treatment lines were switched in 62.1% of treatments: 24.3% due to secondary failure, 20.7% due to primary failure and 3.6% due to side effects. No patient treated with anti-interleukins had to discontinue treatment due to side effects. Ustekinumab had the highest drug survival. Conclusions: This study in the real-world-setting shows maintenance of long-term efficacy and safety of biologic therapy in patients with moderate to severe plaque psoriasis in daily practice who initiated biologic therapy 10 years ago. | es_ES |
dc.description.sponsorship | The journal’s Rapid Service Fee was paid for by Fundación Profesor Novoa Santos (A Coruña. Spain) | |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.relation.uri | https://doi.org/10.1007/s13555-022-00693-2 | es_ES |
dc.rights | Atribución-NoComercial 4.0 Internacional | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Biologic therapy | es_ES |
dc.subject | Psoriasis | es_ES |
dc.subject | Real-world setting | es_ES |
dc.title | Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | Dermatology and Therapy | es_ES |
UDC.volume | 12 | es_ES |
UDC.issue | 3 | es_ES |
UDC.startPage | 761 | es_ES |
UDC.endPage | 770 | es_ES |
dc.identifier.doi | 10.1007/s13555-022-00693-2 |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
II - Artigos [690]